Demographics, healthcare utilization and drug use in children and adults with atopic dermatitis in Denmark: a population‐based cross‐sectional study
Y.M.F. Andersen A. Egeberg L. Skov J.P. Thyssen
First published: 11 January 2019 https://doi.org/10.1111/jdv.15424
Conflicts of interest Dr. Andersen has received research funding from the Lundbeck Foundation, Aage Bang Foundation and A.P. Møller Foundation. Dr. Thyssen has received research a grant from the Lundbeck Foundation attended advisory boards for Roche and Sanofi‐Genzyme and received speaker honorarium from LEO Pharma and Sanofi‐Genzyme. Dr. Skov has received speaker honoraria from AbbVie, Pfizer, Janssen‐Cilag, and Leo Pharma and is a member of the advisory boards of AbbVie, Pfizer, Janssen‐Cilag, Sanofi, Eli Lilly, Celgene and Novartis. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from Leo Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. This research was performed independently through the authors’ academic university and hospital affiliations.
Funding sources The study was funded by a research grant from the Lundbeck Foundation.
Read the full text
ePDFPDFTOOLS SHARE
Abstract
Background
Atopic dermatitis (AD) is a common inflammatory skin condition. While previous publications have examined healthcare expenses, large data regarding patient demographics, healthcare use and drug prescriptions are limited.
Objective
To examine demographics, healthcare use and drug prescriptions in children and adults with hospital‐diagnosed AD.
Methods
Danish nationwide registries were cross‐linked to access demographic, healthcare and drug prescription data on children and adults with hospital‐diagnosed AD (ICD‐10 code L20). The diagnostic code for AD used in this study was validated by reviewing medical charts.
Results
We identified 9704 children (time period 1997–2012) and 5558 adults (time period 1997–2007) with hospital‐diagnosed AD. The diagnostic code L20 had a positive predictive value of 95%. Among children with AD, a larger proportion came from less resourceful families and had immigrant parents from non‐European countries. In adults, we observed an opposite tendency. Topical and systemic antibiotics were used relatively frequent in both children and adults with AD. The use of prednisolone and other systemic anti‐inflammatory therapy was substantially higher in adults with AD than in children.
Limitations
We were unable to identify and describe patients treated by general and private practitioners.
Conclusion
There exist significant differences in social predictors for AD and the use of AD medication between children and adults with hospital‐diagnosed AD in Denmark. The diagnostic code for AD appears to be valid in Danish registries.
Y.M.F. Andersen A. Egeberg L. Skov J.P. Thyssen
First published: 11 January 2019 https://doi.org/10.1111/jdv.15424
Conflicts of interest Dr. Andersen has received research funding from the Lundbeck Foundation, Aage Bang Foundation and A.P. Møller Foundation. Dr. Thyssen has received research a grant from the Lundbeck Foundation attended advisory boards for Roche and Sanofi‐Genzyme and received speaker honorarium from LEO Pharma and Sanofi‐Genzyme. Dr. Skov has received speaker honoraria from AbbVie, Pfizer, Janssen‐Cilag, and Leo Pharma and is a member of the advisory boards of AbbVie, Pfizer, Janssen‐Cilag, Sanofi, Eli Lilly, Celgene and Novartis. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from Leo Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals. This research was performed independently through the authors’ academic university and hospital affiliations.
Funding sources The study was funded by a research grant from the Lundbeck Foundation.
Read the full text
ePDFPDFTOOLS SHARE
Abstract
Background
Atopic dermatitis (AD) is a common inflammatory skin condition. While previous publications have examined healthcare expenses, large data regarding patient demographics, healthcare use and drug prescriptions are limited.
Objective
To examine demographics, healthcare use and drug prescriptions in children and adults with hospital‐diagnosed AD.
Methods
Danish nationwide registries were cross‐linked to access demographic, healthcare and drug prescription data on children and adults with hospital‐diagnosed AD (ICD‐10 code L20). The diagnostic code for AD used in this study was validated by reviewing medical charts.
Results
We identified 9704 children (time period 1997–2012) and 5558 adults (time period 1997–2007) with hospital‐diagnosed AD. The diagnostic code L20 had a positive predictive value of 95%. Among children with AD, a larger proportion came from less resourceful families and had immigrant parents from non‐European countries. In adults, we observed an opposite tendency. Topical and systemic antibiotics were used relatively frequent in both children and adults with AD. The use of prednisolone and other systemic anti‐inflammatory therapy was substantially higher in adults with AD than in children.
Limitations
We were unable to identify and describe patients treated by general and private practitioners.
Conclusion
There exist significant differences in social predictors for AD and the use of AD medication between children and adults with hospital‐diagnosed AD in Denmark. The diagnostic code for AD appears to be valid in Danish registries.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου